CFTR and cystic fibrosis: Paternal exclusion testing by droplet digital PCR (ddPCR) is now also in routine clinical use in France for neurofibromatosis type 1 (NF1) and 2 (NF2), cystic fibrosis (CFTR), as well as several other monogenic conditions where pregnancies are at an increased risk (25% or 50%) of paternal inheritance, in cases with abnormal ultrasound findings, or a previously affected pregnancy[42,59].